AU2018366214B2 - Sustained-release implants for lowering intraocular pressure with extended duration of effect - Google Patents

Sustained-release implants for lowering intraocular pressure with extended duration of effect Download PDF

Info

Publication number
AU2018366214B2
AU2018366214B2 AU2018366214A AU2018366214A AU2018366214B2 AU 2018366214 B2 AU2018366214 B2 AU 2018366214B2 AU 2018366214 A AU2018366214 A AU 2018366214A AU 2018366214 A AU2018366214 A AU 2018366214A AU 2018366214 B2 AU2018366214 B2 AU 2018366214B2
Authority
AU
Australia
Prior art keywords
implant
lactide
weight
eye
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2018366214A
Other languages
English (en)
Other versions
AU2018366214A1 (en
Inventor
Marina BEJANIAN
Michelle Y. Chen
Michael R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2018366214A1 publication Critical patent/AU2018366214A1/en
Priority to AU2024227541A priority Critical patent/AU2024227541A1/en
Application granted granted Critical
Publication of AU2018366214B2 publication Critical patent/AU2018366214B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
AU2018366214A 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect Expired - Fee Related AU2018366214B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227541A AU2024227541A1 (en) 2017-11-09 2024-10-22 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US62/583,967 2017-11-09
US201862683337P 2018-06-11 2018-06-11
US62/683,337 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227541A Division AU2024227541A1 (en) 2017-11-09 2024-10-22 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (2)

Publication Number Publication Date
AU2018366214A1 AU2018366214A1 (en) 2020-05-14
AU2018366214B2 true AU2018366214B2 (en) 2024-11-14

Family

ID=64457124

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018366214A Expired - Fee Related AU2018366214B2 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect
AU2024227541A Pending AU2024227541A1 (en) 2017-11-09 2024-10-22 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227541A Pending AU2024227541A1 (en) 2017-11-09 2024-10-22 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS

Also Published As

Publication number Publication date
CA3080908A1 (en) 2019-05-16
BR112020009224A2 (pt) 2020-10-13
MX2023011426A (es) 2023-10-17
US20240130890A1 (en) 2024-04-25
JP2024032731A (ja) 2024-03-12
JP2021502366A (ja) 2021-01-28
CO2020006924A2 (es) 2020-06-19
CN111315361A (zh) 2020-06-19
AU2018366214A1 (en) 2020-05-14
PH12020550550A1 (en) 2021-03-22
RU2020113494A3 (https=) 2021-12-09
IL273946A (en) 2020-05-31
RU2020113494A (ru) 2021-12-09
KR20200086289A (ko) 2020-07-16
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
MX2020004730A (es) 2020-08-13
WO2019094652A1 (en) 2019-05-16
CL2020001183A1 (es) 2020-11-06
SG11202004126XA (en) 2020-06-29
US20240225893A9 (en) 2024-07-11
AU2024227541A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AU2022200742B2 (en) Prostamide-containing intraocular implants and methods of use thereof
US20240277609A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
AU2018366214B2 (en) Sustained-release implants for lowering intraocular pressure with extended duration of effect
US20130071349A1 (en) Biodegradable polymers for lowering intraocular pressure
US20230026451A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
HK1258014B (en) Prostamide-containing intraocular implants and methods of use thereof
HK1244665A1 (en) Intraocular pressure reduction with intracameral prostamide implants
HK1244665B (en) Intraocular pressure reduction with intracameral prostamide implants

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee